The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 04, 2025
Filed:
Jan. 10, 2018
Applicant:
The General Hospital Corporation, Boston, MA (US);
Inventors:
Marcela V. Maus, Lexington, MA (US);
Matthew Frigault, Somerville, MA (US);
Mark Cobbold, Winchester, MA (US);
Assignee:
The General Hospital Corporation, Boston, MA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/005 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); A61K 40/50 (2025.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/46 (2025.01); C12N 5/0636 (2013.01); A61K 40/50 (2025.01); C12N 2510/00 (2013.01); C12N 2710/16122 (2013.01);
Abstract
The invention provides modified an isolated T lymphocytes having reduced or eliminated expression of the T Cell Receptor, due to reduced or eliminated expression of a CD3ζ, T Cell Receptor Alpha Chain, or T Cell Receptor Beta Chain gene relative to a T lymphocyte without modification, where the isolated T lymphocyte expresses a protein comprising US6, UL40 viral protein and signal peptide, and UL18.